Biological Target definition

Biological Target means AMP-activated protein kinase.
View Source
Biological Target means (a) a biological molecule, as identified by its ENSEMBL ID and (b) any variants of such biological molecule that are also identified by such ENSEMBL ID, including, in the case of this clause (b), any naturally occurring mutant or allelic variants of such biological molecule, such as (i) transcriptional or post-transcriptional isoforms (e.g., alternative splice variants), (ii) post-translational modification variants (e.g., protein processing, maturation and glycosylation variants), or (iii) truncated forms (including fragments).
View Source
Biological Target means any molecular structure, including any protein (such as any NK cell or NK target cell receptor or receptor fragment), any lipid or any glycolipid, or any fragment or derivative of any of the foregoing, such molecular structure being a target for any molecule with pharmaceutical activity. For purposes of illustration, and not limitation, such molecules with pharmaceutical activity include, but are not limited to, antibodies, soluble receptors and other proteins, and any fragments or derivatives of any thereof, and any small molecule.
View Source

Examples of Biological Target in a sentence

  • Additional Biological Targets shall not be deemed to be Potential Collaboration Targets unless (i) MERCK notifies AVEO that it desires to nominate an Additional Biological Target as a Non-MAP Nominated Target, and (ii) AVEO, in its sole discretion, expressly agrees in writing that such Additional Biological Target shall be deemed to be a Potential Collaboration Target.

  • In the event that Merck has abandoned its research efforts directed toward the Biological Target prior to the expiration of the Research Term, Merck may terminate this Agreement upon [***] prior written notice to Metabasis given no earlier than the [***].

  • This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning the Biological Target.

  • IPH covenants and agrees that neither IPH nor any of its Affiliates will at any time during the Term develop or commercialize any therapeutic, prophylactic or diagnostic product comprised of or directed to the same Biological Target as any Licensed Product, Residual Product or Niche Candidate being developed or marketed solely by NN or its Affiliates (or Out-licensees thereof).

  • For the avoidance of doubt, NN shall have no research funding obligation with respect to, and IPH shall not assign any FTEs funded by NN hereunder to, any activities in connection with the research, development or commercialization of or under any IPR (or any Know-How, Biological Target or other subject matter encompassed by such IPR) that is in-licensed or otherwise acquired by IPH pursuant to this Subsection 3.4.3.

Related to Biological Target

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Opioid antagonist means a drug that binds to opioid

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.